文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

SpaceOAR水凝胶间隔物真实世界医疗器械报告:FDA MAUDE数据库分析

Real-World Medical Device Reports of SpaceOAR Hydrogel Spacer: Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) Database.
PubMed 文献 · Adv Radiat Oncol · 2025-06-07

该研究基于美国FDA MAUDE数据库2015至2023年数据,分析聚乙二醇水凝胶间隔物的医疗器械报告(MDR),并与同期美国销售数据关联。共识别1005份MDR,销售251836个单位,年MDR率从2015年0.00%升至2023年0.57%(总体0.40%)。最常见的器械相关事件为放置/定位问题(0.295%),患者事件以无症状(0.175%)和疼痛/不适(0.110%)为主,死亡报告5例(0.002%)。

要点

  • 总体器械相关事件和患者事件率均低于1%,多数无临床后果。
  • 年MDR率从2015年0.00%上升至2023年0.57%,总体0.40%。
  • 最常见患者事件为无症状(0.175%)、疼痛/不适(0.110%)、感染(0.052%)、瘘形成(0.037%)、出血(0.033%)。

核心结论

  • 相对于美国估计的器械使用量,PEG水凝胶间隔物的总体器械相关事件和患者事件率持续低于1%,且大多数报告无或仅有轻微临床后果。

研究设计与样本

  • 共识别1005份来自美国的唯一MDR,同期销售251836个间隔物单位。

主要发现

  • 报告死亡5例,占总销售单位的0.002%。
  • 年MDR率从2015年的0.00%上升至2023年的0.57%,总体率为0.40%。
  • 最常见的器械相关事件为放置/定位问题(0.295%)和无明确器械或使用问题的不良事件(0.084%)。
  • 最常见的患者事件为无临床体征、症状或无症状(0.175%)、疼痛/不适(0.110%)、感染(0.052%)、瘘形成(0.037%)和出血/失血/流血(0.033%)。

临床怎么用

  • 临床医生应了解PEG水凝胶间隔物相关事件总体发生率低,但需关注放置/定位问题及罕见但严重的瘘形成和感染等事件。

局限性

  • MDR报告可能存在漏报和报告偏倚,且销售单位数不一定等于实际置入数,计算的发生率仅为估计值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Increasingly, polyethylene glycol (PEG) hydrogel spacers are being used to help reduce rectal toxicity in men undergoing radiation therapy for prostate cancer. Device-related issues and patient event rates from the Manufacturer and User Facility Device Experience (MAUDE) were assessed to contextualize spacer reports in the United States. METHODS AND MATERIALS: PEG hydrogel spacer medical device reports (MDRs) from January 1, 2015, through December 31, 2023, were collected from the MAUDE database, which reports suspected device-associated malfunctions, injuries, and deaths submitted to the United States Food and Drug Administration. United States sales data during the same period were obtained from the manufacturer. Reported rates of device-related and patient events were calculated by dividing MDRs by total units sold, recognizing that not all units sold are necessarily placed. RESULTS: A total of 1005 unique MDRs reported from the United States for PEG hydrogel spacers were identified in the MAUDE database, and 251,836 spacer units were sold during the study period. Five deaths were reported, representing 0.002% of total units sold. The annual MDR rate increased from 0.00% in 2015 to 0.57% in 2023 (overall rate 0.40%). The most frequently reported device-related events were placement/positioning problems (0.295%) and adverse events without an identified device or use problem (0.084%). The most frequently reported patient events were "no clinical signs, symptoms, or conditions" or asymptomatic (0.175%), pain/discomfort (0.110%), infection (0.052%), fistula formation (0.037%), and hemorrhage/blood loss/bleeding (0.033%). CONCLUSIONS: With respect to estimated device usage in the United States, overall device-related events and patient event rates for PEG hydrogel spacers consistently remained below 1%, with the majority having minimal or no reported clinical consequence.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hathout L, Shin YE, Rojanasarot S, et al. Real-World Medical Device Reports of SpaceOAR Hydrogel Spacer: Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) Database. Adv Radiat Oncol. 2025. PMID: 41321862. doi:10.1016/j.adro.2025.101824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。